Abstracts tagged "Drug toxicity"

Abstract Number: 1631 • ACR Convergence 2020
No Increased Risk of Liver Dysfunction from Tildrakizumab Treatment: Post Hoc Analyses of the Tildrakizumab Psoriasis Clinical Program
Mark Lebwohl¹, Darren West², Alan Mendelsohn³, Stephen Rozzo³ and Giampiero Girolomoni⁴, ¹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ²Spectrum Dermatology, Scottsdale, AZ, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁴Section of Dermatology, Department of Medicine, University of Verona, Verona, Italy
Background/Purpose: Tildrakizumab (TIL) is a high‐affinity, humanized, immunoglobulin G1κ, anti–interleukin-23p19 monoclonal antibody approved for the treatment of moderate to severe plaque psoriasis. We evaluated adverse…
Abstract Number: 321 • 2019 ACR/ARP Annual Meeting
Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Rheumatoid Arthritis and Systemic Lupus Erythematosus
Tara Skorupa¹ and Robert Shmerling ¹, ¹Beth Israel Deaconess Medical Center / Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly prescribed medication for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other rheumatic diseases. However, HCQ may cause retinal…
Abstract Number: 1713 • 2019 ACR/ARP Annual Meeting
Drug-induced IgA Vasculitis: Data from the French Pharmacovigilance Network and the WHO VigiBase
CAMILLE RASMUSSEN¹, MYLENE TISSEYRE ², JULIE GARON-CZMIL ², MARINA ATZENHOFFER ³, Loïc Guillevin ⁴, LAURENT CHOUCHANA ² and Benjamin Terrier ⁴, ¹Cochin Hospital, National Referral Center for Rare Systemic Autoimmune Diseases, PARIS, PARIS, France, ²PHARMACOVIGILANCE, COCHIN HOSPITAL, PARIS, PARIS, France, ³PHARMACOVIGILANCE CENTER LYON, FRANCE, LYON, France, ⁴National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France
Background/Purpose: IgA vasculitis (IgAV) is an immune complex small-vessel vasculitis, with IgA1-dominant immune deposits. Drug-induced IgAV were rarely reported in the literature, but no systematic…
Abstract Number: 819 • 2018 ACR/ARHP Annual Meeting
Use of Takayasu Arteritis Damage Score (TADS) to Measure Damage in Takayasu Arteritis
Sivakumar Mambakkam Rajappa¹ and Krishnamurthy Venkataraman², ¹Rheumatology and Immunology, GLB Hospitals, Chennai, India, ²Rheumatology, Apollo Speciality Hospitals, Chennai, India
Background/Purpose: Takayasu Arteritis (TA) in India frequently present with complications, indicating the need for a specific damage index to capture the accumulation of disease-related scars…
Abstract Number: 1038 • 2018 ACR/ARHP Annual Meeting
Tenofovir, a Nucleoside Analog Reverse Transcriptase Inhibitor for Treatment of HIV, Promotes Osteoclast Differentiation and Decreases Osteoblast Formation By a Mechanism Depending on ATP Release and Adenosine
Francisco Miguel Conesa-Buendia¹, Patricia Llamas², Raquel Largo³, Gabriel Herrero-Beaumont³, Bruce N. Cronstein⁴ and Aranzazu Mediero⁵, ¹Bone and Joint Research Unit, IIS-Fundacion Jimenez Diaz- UAM, Madrid, Spain, ²Bone and Joint Research Unit, IIS-Fundacion Jimenez Díaz-UAM, Madrid, Spain, ³Bone and Joint Research Unit, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, ⁴Rheumatology, New York University School of Medicine, Division of Rheumatology, New York, NY, ⁵Joint and Bone Research Unit, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain
Background/Purpose: Human Immunodeficiency Virus (HIV) infection devastates the immune system but also affects tissues and organs such as kidney, liver, central nervous system, heart and…
Abstract Number: 1039 • 2018 ACR/ARHP Annual Meeting
Tenofovir Induces Osteopenia and Dipyridamole, an Inhibitor of the Ent-1 Nucleoside Transporter, Reverses the Osteopenic Effect of Tenofovir In Vivo
Francisco Miguel Conesa-Buendia¹, Patricia Llamas², Tuere Wilder³, Raquel Largo⁴, Gabriel Herrero-Beaumont⁴, Bruce N. Cronstein⁵ and Aranzazu Mediero⁶, ¹Bone and Joint Research Unit, IIS-Fundacion Jimenez Diaz- UAM, Madrid, Spain, ²Bone and Joint Research Unit, IIS-Fundacion Jimenez Díaz-UAM, Madrid, Spain, ³Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ⁴Bone and Joint Research Unit, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, ⁵Rheumatology, New York University School of Medicine, Division of Rheumatology, New York, NY, ⁶Joint and Bone Research Unit, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain
Background/Purpose: Osteopenia and fragility fractures have been associated with HIV infection. Tenofovir, one of the most commonly used antivirals in HIV, also leads to increases…
Abstract Number: 2146 • 2018 ACR/ARHP Annual Meeting
A Meta-Analysis of the Prevalence and Risk Factors for Retinal Toxicity in Rheumatologic Patients on Hydroxychloroquine Therapy
Amanda Worme¹, Leonardo Tamariz², Ana Palacio², Zsuzsanna Nemeth³ and Mathew Farbman⁴, ¹Internal Medicine, University of Miami Miller School of Medicine at Holy Cross Hospital, Fort Lauderdale, FL, ²Internal Medicine, University of Miami Miller School of Medicine, Miami, FL, ³Health Informatics, University of Miami Miller School of Medicine, Miami, FL, ⁴Rheumatology, University of Miami Miller School of Medicine at Holy Cross Hospital, Fort Lauderdale, FL
Background/Purpose: HCQ is one of the most common DMARD(s) used in treatment of several rheumatologic diseases, including RA and SLE. Although rare, retinal toxicity remains…
Abstract Number: 2634 • 2018 ACR/ARHP Annual Meeting
The Risk of Hydroxychloroquine Retinopathy in an SLE Cohort: Screening and Prevention in Clinical Practice
Caroline Siegel¹, Jennifer M. Grossman², John Fitzgerald³, Bevra H Hahn⁴, Sarah Chen⁵, Lori Sahakian⁴, Eloise Olmos², Michael B. Gorin⁶ and Maureen A. McMahon², ¹Department of Internal Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ³Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁴UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Department of Ophthalmology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication for SLE because of its highly favorable risk-benefit ratio. Drug-induced retinopathy is one of very few serious…
Abstract Number: 1340 • 2016 ACR/ARHP Annual Meeting
Type and Frequency of Immune-Related Adverse Reactions in Patients Treated with Pembrolizumab (Keytruda), a Monoclonal Antibody Directed Against PD-1, in Advanced Melanoma at a Single Institution
Olga Pinkston¹, Florentina Berianu¹ and Benjamin Wang², ¹Rheumatology, Mayo Clinic, Jacksonville, FL, ²Division of Rheumatology, Mayo Clinic, Jacksonville, FL
Background/Purpose: Although immune checkpoint inhibitors improve survival in patients with melanoma and other cancers, the alterations to the immune system induced by these medications can…
Abstract Number: 2970 • 2016 ACR/ARHP Annual Meeting
Incidence and Characteristics of Vasculitis Associated with Monoclonal Antibodies and Peptide Fusion Proteins: A Survey from the French National Pharmacovigilance Database
Bertrand Lioger^1,2, Fanny Hennekinne¹, Marie-Sara Agier³, Annie-Pierre Jonville-Bera^3,4 and François Maillot^1,5, ¹Internal Medicine, Tours University Hospital, Tours, France, ²GICC UMR 7292, University François Rabelais, Tours, France, ³Clinical Pharmacology, Tours University Hospital, Tours, France, ⁴Regional Pharmacovigilance Center, Tours University Hospital, Tours, France, ⁵INSERM U1069, University François Rabelais, Tours, France
Background/Purpose: Immunological classes of adverse events (AEs), including the immune related AEs and the paradoxical effects, have emerged with the used of biologics. Among them,…
Abstract Number: 1024 • 2015 ACR/ARHP Annual Meeting
Disruptions in Folate Homeostasis May Lead to Increased Risk for Methotrexate Intolerance in Juvenile Idiopathic Arthritis
Mara L Becker¹, Leon van Haandel², Ryan Funk³, Rodger Gaedigk⁴ and J.S. Leeder⁵, ¹Rheumatology, Children's Mercy Kansas City, Kansas City, MO, ²Clinical Pharmacology, Medical Toxicology, and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, MO, ³University of Kansas Medical Center, Kansas City, KS, ⁴Clinical Pharmacology, medical Toxicology and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, MO, ⁵Clinical Pharmacology, Medical Toxicology and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, MO
Background/Purpose: Despite widespread use, there remain no clear predictors of methotrexate (MTX) response or toxicity in Juvenile Idiopathic Arthritis (JIA). With the utilization of new…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].